Watch a 28-minute webinar exploring innovative treatment approaches for pancreatic cancer, delivered by PhD candidate Jonathan DeLiberty from the laboratories of Drs. Kirsten Bryant and Channing Der. Dive into research findings on pancreatic ductal adenocarcinoma (PDAC), focusing on the relationship between KRAS pathway inhibition and autophagy dependency. Learn about the limitations of current FDA-approved autophagy inhibitors chloroquine/hydroxychloroquine (CQ/HCQ) and discover potential new strategies for more effective anti-autophagy treatments. The presentation draws from DeLiberty's extensive research background, including his work at the University of Pittsburgh studying non-steroidal anti-inflammatory induction of immunogenic cell death in colorectal cancer. Healthcare professionals can earn PACE credits through Labroots upon completion of the webinar, valid until October 2026.
Overview
Syllabus
Concurrent Inhibition of The RAS Pathway and Autophagy As a Treatment Approach for Pancreatic Cancer
Taught by
Labroots